U.S., Nov. 7 -- ClinicalTrials.gov registry received information related to the study (NCT07921576) titled 'Phase 1/2 Study of DS010 in Advanced Cancer Patients With Cachexia' on Nov. 02.
Brief Summary: A study to evaluate the safety, tolerability, and preliminary efficacy of DS010 in patients with cancer and cachexia
Study Start Date: Nov. 30
Study Type: INTERVENTIONAL
Condition:
Cancer
Cachexia
Intervention:
DRUG: DS010 injection
Once every 3 weeks intravenously injection
Recruitment Status: RECRUITING
Sponsor: Dartsbio Pharmaceuticals Ltd.
Published by HT Digital Content Services with permission from Health Daily Digest....